20(R)-Ginsenoside Rh2

Cat. No.: HY-N1401 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

20(R)-Ginsenoside Rh2, a matrix metalloproteinase (MMP) inhibitor, acts as a cell antiproliferator. It has anticancer effects via blocking cell proliferation and causing G1 phase arrest. 20(R)-Ginsenoside Rh2 induces apoptosis, and has anti-inflammatory and antioxidative activity. 20(R)-Ginsenoside Rh2 inhibits the replication and proliferation of mouse and human gammaherpesvirus 68 (MHV-68) with an IC₅₀ of 2.77 μM for murine MHV-68.

For research use only. We do not sell to patients.

20(R)-Ginsenoside Rh2 Chemical Structure

CAS No. : 112246-15-8

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 159	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 159	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 116	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 174	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 310	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE 20(R)-Ginsenoside Rh2

•Sci Adv. 2023 Jan 20;9(3):eadd3867. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

View All Isoforms

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

Biological Activity
Purity & Documentation
References
Customer Review

Description

20(R)-Ginsenoside Rh2, a matrix metalloproteinase (MMP) inhibitor, acts as a cell antiproliferator. It has anticancer effects via blocking cell proliferation and causing G1 phase arrest. 20(R)-Ginsenoside Rh2 induces apoptosis, and has anti-inflammatory and antioxidative activity^[1]^[2]^[3]. 20(R)-Ginsenoside Rh2 inhibits the replication and proliferation of mouse and human gammaherpesvirus 68 (MHV-68) with an IC₅₀ of 2.77 μM for murine MHV-68^[4].

IC₅₀ & Target

MMP^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	38 μM Compound: Rh2	Antiproliferative activity against human DU-145 cells incubated for 3 days Antiproliferative activity against human DU-145 cells incubated for 3 days	[PMID: 32702586]
HCT-116	IC₅₀	19.6 μM Compound: Rh2	Cytotoxicity against human HCT-116 assessed as reduction in cell viability by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability by MTT assay	[PMID: 32702586]
HCT-116	IC₅₀	35 μM Compound: Rh2	Induction of cell death in human HCT-116 cells incubated for 48 hrs by trypan blue staining based analysis Induction of cell death in human HCT-116 cells incubated for 48 hrs by trypan blue staining based analysis	[PMID: 32702586]
HeLa	IC₅₀	2.52 μg/mL Compound: Rh2	Induction of apoptosis in human HeLa cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human HeLa cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
HepG2	IC₅₀	1.648 μg/mL Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 72 hrs Induction of apoptosis in human HepG2 cells incubated for 72 hrs	[PMID: 32702586]
HepG2	IC₅₀	100 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 48 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 cells incubated for 48 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	129.2 μM Compound: Rh2	Induction of apoptosis in human HepG2 beta-catenin cells incubated for 48 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 beta-catenin cells incubated for 48 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	42.12 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 24 hrs Induction of apoptosis in human HepG2 cells incubated for 24 hrs	[PMID: 32702586]
HepG2	IC₅₀	58.12 μM Compound: Rh2	Induction of apoptosis in human HepG2 cells incubated for 72 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 cells incubated for 72 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HepG2	IC₅₀	83.33 μM Compound: Rh2	Induction of apoptosis in human HepG2 beta-catenin cells incubated for 72 hrs by PI/Annexin V-FITC analysis Induction of apoptosis in human HepG2 beta-catenin cells incubated for 72 hrs by PI/Annexin V-FITC analysis	[PMID: 32702586]
HL-60	IC₅₀	25.59 μM Compound: Rh2	Induction of apoptosis in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of apoptosis in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32702586]
HL-60	IC₅₀	38 μM Compound: Rh2	Cytotoxicity against human HL-60 cells measured after 24 hrs by MTT assay Cytotoxicity against human HL-60 cells measured after 24 hrs by MTT assay	[PMID: 32702586]
Jurkat	IC₅₀	35 μM Compound: Rh2	Inhibition of proliferation in human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Inhibition of proliferation in human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
K562	IC₅₀	60 μM Compound: Rh2	Cytotoxicity against human K562 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
Kasumi 1	IC₅₀	60.06 μM Compound: Rh2	Induction of apoptosis in human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Induction of apoptosis in human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32702586]
KG-1	IC₅₀	60 μM Compound: Rh2	Cytotoxicity against human KG-1 alpha cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human KG-1 alpha cells incubated for 48 hrs by CCK-8 assay	[PMID: 32702586]
LNCaP	IC₅₀	17 μM Compound: Rh2	Antiproliferative activity against human LNCaP cells incubated for 3 days Antiproliferative activity against human LNCaP cells incubated for 3 days	[PMID: 32702586]
PC-3	IC₅₀	35 μM Compound: Rh2	Antiproliferative activity against human PC-3 cells incubated for 3 days Antiproliferative activity against human PC-3 cells incubated for 3 days	[PMID: 32702586]
SK-HEP1	IC₅₀	3.15 μg/mL Compound: Rh2	Induction of apoptosis in human SK-HEP1 cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human SK-HEP1 cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
SW480	IC₅₀	35 μM Compound: Rh2	Induction of cell death in human SW480 cells incubated for 48 hrs by trypan blue staining based analysis Induction of cell death in human SW480 cells incubated for 48 hrs by trypan blue staining based analysis	[PMID: 32702586]
SW480	IC₅₀	4.06 μg/mL Compound: Rh2	Induction of apoptosis in human SW480 cells incubated for 2 hrs by fluorescence microscopic analysis Induction of apoptosis in human SW480 cells incubated for 2 hrs by fluorescence microscopic analysis	[PMID: 32702586]
U-937	IC₅₀	38 μM Compound: Rh2	Cytotoxicity against human U-937 cells measured after 24 hrs by MTT assay Cytotoxicity against human U-937 cells measured after 24 hrs by MTT assay	[PMID: 32702586]

Molecular Weight

622.87

Formula

C₃₆H₆₂O₈

CAS No.

112246-15-8

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1O[C@H]2CC[C@]3(C)[C@@]4([H])C[C@@H](O)[C@@H]5[C@@H]([C@](C)(O)CC/C=C(C)\C)CC[C@](C)5[C@@](C)4CC[C@@]3([H])C2(C)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (200.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6055 mL	8.0274 mL	16.0547 mL
5 mM	0.3211 mL	1.6055 mL	3.2109 mL
10 mM	0.1605 mL	0.8027 mL	1.6055 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (274 KB) SDS (251 KB)

COA (251 KB) HNMR (283 KB)

Handling Instructions (2659 KB)

References

[1]. Choi WY, et al. Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory properties of 20(R)-ginsenoside Rh2 in cultured macrophages and keratinocytes. J Pharm Pharmacol. 2013 Feb;65(2):310-6. [Content Brief]

[2]. Chung KS, et al. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression. Carcinogenesis. 2013 Feb;34(2):331-40. [Content Brief]

[3]. Choi S, et al. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res. 2009 Oct;26(10):2280-8. [Content Brief]

[4]. Kang S, et al. Antiviral activity of 20(R)-ginsenoside Rh2 against murine gammaherpesvirus. J Ginseng Res. 2017 Oct;41(4):496-502. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6055 mL	8.0274 mL	16.0547 mL	40.1368 mL
	5 mM	0.3211 mL	1.6055 mL	3.2109 mL	8.0274 mL
	10 mM	0.1605 mL	0.8027 mL	1.6055 mL	4.0137 mL
	15 mM	0.1070 mL	0.5352 mL	1.0703 mL	2.6758 mL
	20 mM	0.0803 mL	0.4014 mL	0.8027 mL	2.0068 mL
	25 mM	0.0642 mL	0.3211 mL	0.6422 mL	1.6055 mL
	30 mM	0.0535 mL	0.2676 mL	0.5352 mL	1.3379 mL
	40 mM	0.0401 mL	0.2007 mL	0.4014 mL	1.0034 mL
	50 mM	0.0321 mL	0.1605 mL	0.3211 mL	0.8027 mL
	60 mM	0.0268 mL	0.1338 mL	0.2676 mL	0.6689 mL
	80 mM	0.0201 mL	0.1003 mL	0.2007 mL	0.5017 mL
	100 mM	0.0161 mL	0.0803 mL	0.1605 mL	0.4014 mL